{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-24-000069","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2024-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.072546+00:00","generated_at":"2026-05-30T10:03:56.756886+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"vTv Therapeutics receives termination notice for ppar-δ license from OnKure; effective Jan 2025","bullets":["OnKure (formerly Reneo) notified vTv LLC intent to terminate the December 2017 License Agreement for vTv's ppar-δ agonist program IP.","OnKure has decided to discontinue development of the licensed program.","Termination becomes effective January 20, 2025.","Agreement had been previously amended in December 2021.","Financial impact of the termination was not disclosed by vTv."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-24-000069","json":"https://secwatch.observer/filing/0001641489-24-000069.json","markdown":"https://secwatch.observer/filing/0001641489-24-000069.md","text":"https://secwatch.observer/filing/0001641489-24-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000069/0001641489-24-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000069/vtvt-20241022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:03:56.756886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}